Lantern Pharma Inc.
LTRNHealthcare|Biotechnology|US
$0.57
+0.04 (+6.75%)
Cash / Share
$0.59
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05933265 Study of LP-184 in Patients With Advanced Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor | P1P2 | Active | 64 | Open-label | LP-184, Olaparib, Nivolumab & Ipilimumab |
| NCT05456256 A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung | P2 | Recruiting | 90 | RCT, Open-label | LP-300, Pemetrexed, Carboplatin |
| NCT06132503 Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | Relapsed or Refractory Lymphomas, Advanced Solid Tumor | P1 | Recruiting | 110 | Open-label | LP-284 |
| NCT00966914 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin | Non-small Cell Lung Cancer | P3 | Completed | 540 | RCT, Double-blind | Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel, Placebo in combination with cisplatin and docetaxel or paclitaxel |
| NCT00039780 Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel | Breast Neoplasms, Breast Diseases | P3 | Completed | 764 | RCT, Double-blind | BNP7787, Placebo |
| NCT03643107 Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Metastatic Castration-Resistant Prostate Cancer Patients | P2 | Completed | 15 | Open-label | Irofulven |